Blue Cross Blue Shield Association, Technology Evaluation Center (BCBS TEC) – BCBS TEC concluded that there is sufficient evidence to conclude clinical validity or utility of EGFR mutation testing to predict response to erlotinib and to guide treatment decisions in patients with NSCLC [4]. Here, EGFR is linked to non-small cell lung carcinoma.